Pacific Biosciences Of California (PACB) Share-based Compensation (2010 - 2026)

Pacific Biosciences Of California has reported Share-based Compensation for 17 years, with the latest figure at $9.3 million in Q2 2026.

• On a quarterly basis, Share-based Compensation changed N/A year-over-year to $9.3 million in Q2 2026; TTM through Jun 2026 was $25.8 million, a 59.58% decrease from a year earlier, with the FY2025 full-year figure at $41.7 million, down 41.34% from the prior year.
• Share-based Compensation was $9.3 million for Q2 2026 at Pacific Biosciences Of California, up from $4.5 million in the prior quarter.
• The five-year high for Share-based Compensation was $29.6 million in Q1 2025, with the low at $2.5 million in Q3 2025.
• Average Share-based Compensation over 5 years is $16.3 million, with a median of $18.0 million recorded in 2023.
• The largest YoY upside for Share-based Compensation was 51.47% in 2025 against a maximum downside of 86.28% in 2025.
• Over 5 years, Share-based Compensation stood at $18.0 million in 2022, then dropped by 7.64% to $16.6 million in 2023, then declined by 3.32% to $16.0 million in 2024, then plunged by 40.2% to $9.6 million in 2025, then dropped by 3.39% to $9.3 million in 2026.
• The last three Share-based Compensation figures came in at $9.3 million (Q2 2026), $4.5 million (Q1 2026), and $9.6 million (Q4 2025), per Business Quant data.